Indication
Food IgE-mediated Allergy
1 clinical trial
2 products
Clinical trial
A 15 Months, Double-Blind, Randomized Controlled Trial Comparing 20 Weeks of Two Dosages of Omalizumab to Placebo to Accelerate a Symptom-driven Oral Immunotherapy Schedule in Subjects Aged 6 to 25 Years With Multiple Food AllergiesStatus: Recruiting, Estimated PCD: 2024-12-01
Product
OmalizumabProduct
Placebo